Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 158 of the 159 references it cites were found in a registry or an index.

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Open access
Sposito, Andrei C., Berwanger, Otávio, de Carvalho, Luiz Sérgio F., Saraiva, José Francisco Kerr · 2018 · Cardiovascular Diabetology

Abstract

Patients with type 2 diabetes (T2DM) have a substantial risk of developing cardiovascular disease. The strong connection between the severity of hyperglycaemia, metabolic changes secondary to T2DM and vascular damage increases the risk of macrovascular complications. There is a challenging demand for the development of drugs that control hyperglycaemia and influence other metabolic risk factors to improve cardiovascular outcomes such as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina and heart failure (major adverse cardiovascular events). In recent years, introduction of the new drug class of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has changed the treatment landscape as GLP-1RAs have become well-established therapies in T2DM. The benefits of GLP-1RAs are derived from their pleiotropic effects, which include appetite control, glucose-dependent secretion of insulin and inhibition of glucagon secretion. Importantly, their beneficial effects extend to the cardiovascular system. Large clinical trials have evaluated the cardiovascular effects of GLP-1RAs in patients with T2DM and elevated risk of cardiovascular disease and the results are very promising. However, important aspects still require elucidation, such as the specific mechanisms involved in the cardioprotective effects of these drugs. Careful interpretation is necessary because of the heterogeneity across the trials concerning the definition of cardiovascular risk or cardiovascular disease, baseline characteristics, routine care and event rates. The aim of this review is to describe the main clinical aspects of the GLP-1RAs, compare them using data from both the mechanistic and randomized controlled trials and discuss potential reasons for improved cardiovascular outcomes observed in these trials. This review may help clinicians to decide which treatment is most appropriate in reducing cardiovascular risk in patients with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-018-0800-2

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Forest plots showing the effects of GLP-1- and non-GLP-1-based therapies on a MACE, b myocardial infarction
Fig. 1 Forest plots showing the effects of GLP-1- and non-GLP-1-based therapies on a MACE, b myocardial infarctionCC BY · PubMed Central
Fig. 2 Forest plots showing the effects of GLP-1- and non-GLP-1-based therapies on cardiovascular death
Fig. 2 Forest plots showing the effects of GLP-1- and non-GLP-1-based therapies on cardiovascular deathCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 159 references

Research works printed but not linked: 1

  1. IDF Diabetes Atlas 8th edition. 2017. https://www.idf.org/e-library/welcome.html . Accessed 16 Feb 2018.

Cited by

See all 178

Metadata

Authors
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K.
Affiliations
  • Universidade Estadual de Campinas (UNICAMP) (BR)
  • Pontifícia Universidade Católica de Campinas (BR)
Corresponding author
Sposito, Andrei C.
Venue
Cardiovascular Diabetology
Published
2018-12
Volume
17
Issue
1
Pages
157-157
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2905322153
Cited by
171
References
159
Citations by year
2026: 11 · 2025: 18 · 2024: 17 · 2023: 14 · 2022: 25 · 2021: 15 · 2020: 51 · 2019: 18
FWCI
3.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, type 2 diabetes, cardiovascular outcomes, cardioprotection, major adverse cardiovascular events, hyperglycemia, insulin secretion, glucagon inhibition, appetite regulation, cardiovascular risk reduction
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Risk Factors, Signal Transduction, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. https://app.cochat.ai/papers/10.1186/s12933-018-0800-2
The paper
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018). GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-018-0800-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.